The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Berk, MD
Arcutis Biotherapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arcutis Clinical Site 11
Surrey, British Columbia, Canada
- Arcutis Clinical Site 18
Surrey, British Columbia, Canada
- Arcutis Clinical Site 38
Winnipeg, Manitoba, Canada
- Arcutis Clinical Site 10
Ajax, Ontario, Canada
- Arcutis Clinical Site 25
London, Ontario, Canada
- Arcutis Clinical Site 26
Markham, Ontario, Canada
- Arcutis Clinical Site 32
Oakville, Ontario, Canada
- Arcutis Clinical Site 17
Peterborough, Ontario, Canada
- Arcutis Clinical Site 30
Waterloo, Ontario, Canada
- Arcutis Clinical Site 36
Windsor, Ontario, Canada
- Arcutis Clinical Site 35
Beverly Hills, California, United States
- Arcutis Clinical Site 29
Northridge, California, United States
- Arcutis Clinical Site 28
San Diego, California, United States
- Arcutis Clinical Site 27
Santa Monica, California, United States
- Arcutis Clinical Site 12
Miami, Florida, United States
- Arcutis Clinical Site 16
Sanford, Florida, United States
- Arcutis Clinical Site 21
Louisville, Kentucky, United States
- Arcutis Clinical Site 34
Clinton Township, Michigan, United States
- Arcutis Clinical Site 33
Detroit, Michigan, United States
- Arcutis Clinical Site 20
Fridley, Minnesota, United States
- Arcutis Clinical Site 22
New York, New York, United States
- Arcutis Clinical Site 14
High Point, North Carolina, United States
- Arcutis Clinical Site 39
Bexley, Ohio, United States
- Arcutis Clinical Site 15
Pittsburgh, Pennsylvania, United States
- Arcutis Clinical Site 19
College Station, Texas, United States
- Arcutis Clinical Site 13
Houston, Texas, United States
- Arcutis Clinical Site 37
Houston, Texas, United States
- Arcutis Clinical Site 23
San Antonio, Texas, United States
- Arcutis Clinical Site 24
Webster, Texas, United States
- Arcutis Clinical Site 31
Norfolk, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Sept 2018
- Primary completion
- 29 May 2019
- Completion
- 29 May 2019
- Last update posted
- 2 Sept 2022
- Registered enrollment
- 331
- Registry id
- NCT03638258
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.